Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas ® EGFR mutation test
Authors:
- Miyako SatouchiMSMiyako Satouchi
- Hiroshi TanakaHTHiroshi Tanaka
- Hiroshige YoshiokaHYHiroshige Yoshioka
- Tadasuke ShimokawajiTSTadasuke Shimokawaji
- Keiko MizunoKMKeiko Mizuno
- Koji TakedaKTKoji Takeda
- Ichiro YoshinoIYIchiro Yoshino
- Takashi SetoTSTakashi Seto
- Takayasu KurataTKTakayasu Kurata
- Naoki TashiroNTNaoki Tashiro
- Koichi HagiwaraKHKoichi Hagiwara
Open Access
- 11 July 2017
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 111, 190-194
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samplesJournal of Clinical Pathology, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR InhibitorsScience Translational Medicine, 2011
- Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based AssayClinical Cancer Research, 2011
- Detection of EGFR Gene Mutations Using the Wash Fluid of CT-Guided Biopsy Needle in NSCLC PatientsJournal of Thoracic Oncology, 2008
- Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancersBritish Journal of Cancer, 2007
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLOS Medicine, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004